Written Communication by the Subject Company Relating to a Third Party Tender Offer (sc14d9c)
June 19 2018 - 4:30PM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE
14D-9
(RULE
14d-101)
SOLICITATION/RECOMMENDATION STATEMENT UNDER
SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934
Foundation Medicine, Inc.
(Name of Subject Company)
Foundation
Medicine, Inc.
(Name of Person(s) Filing Statement)
Common Stock, par value $0.0001 per Share
(Title of Class of Securities)
350456100
(CUSIP Number of
Class of Securities)
Robert W. Hesslein
Senior Vice President and General Counsel
150 Second Street
Cambridge MA, 02141
(617)
418-2200
(Name, Address and Telephone Number of Person Authorized to Receive Notices
and Communications on Behalf of the Person(s) Filing Statement)
With copies to:
Stuart M.
Cable
Lisa R. Haddad
Goodwin Procter LLP
100
Northern Avenue
Boston, MA 02210
(617)
570-1000
☒
|
Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.
|
The information set forth under Items 1.01 and 7.01 of the Current Report on
Form 8-K
filed by Foundation
Medicine, Inc. on June 19, 2018 (including all exhibits attached thereto) is incorporated herein by reference.
Foundation Medicine, Inc. (NASDAQ:FMI)
Historical Stock Chart
From Jun 2024 to Jul 2024
Foundation Medicine, Inc. (NASDAQ:FMI)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Foundation Medicine, Inc. (delisted) (NASDAQ): 0 recent articles
More Foundation Medicine, Inc. News Articles